L'intérêt à découvert pour CNS Pharma donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de CNS Pharma. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

CNS Pharma (NASDAQ:CNSP) Stock, Rapport sur les intérêts à découvert

CNS Pharmaceuticals

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

CNS Pharmaceuticals Inc

<p>During the last three months, 5 analysts shared their evaluations of Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $370.0, along with a high estimate of $400.00 and a low estimate of $350.00. This upward trend is evident, with the current average reflecting a 2.42% increase from the previous average price target of $361.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451268_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Snap-on among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macgregor</td>
<td>Longbow Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$400.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Snap-on. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Snap-on compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Snap-on's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Snap-on's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Snap-on analyst ratings.</strong></a></p>
<h2>Discovering Snap-on: A Closer Look</h2>
<p>Snap-on manufactures premium tools and software for repair professionals. Hand tools are sold through a franchisee-operated mobile van network that serve auto technicians who purchase tools at their own expense. A unique element of its business model is that franchisees bear significant risk, as they must invest in the mobile van, inventory, and software. At the same time, franchisees extend personal credit directly to technicians on an individual tool basis. Snap-on currently operates three segments: repair systems and information, commercial and industrial, and tools. Its finance arm provides financing to franchisees to run their operations, which includes offering loans and leases for mobile vans.</p>
<h3>Snap-on: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Snap-on's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>0.18%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Snap-on's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.53%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Snap-on's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>4.75%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.26%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.24</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Demystifying Snap-on: Insights From 5 Analyst Reviews

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Home Depot</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Home Depot.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 28% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $119,477, and 10 are calls, for a total amount of $1,564,142.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $415.0 for Home Depot, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Home Depot options trades today is 484.31 with a total volume of 1,809.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Home Depot's big money trades within a strike price range of $200.0 to $415.0 over the last 30 days.</p>
<h3>Home Depot Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451267_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$31.1</td>
<td>$29.6</td>
<td>$31.1</td>
<td>$380.00</td>
<td>$622.0K</td>
<td>51</td>
<td align="right">200</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.9</td>
<td>$410.00</td>
<td>$361.9K</td>
<td>1.7K</td>
<td align="right">937</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$25.25</td>
<td>$25.1</td>
<td>$25.25</td>
<td>$350.00</td>
<td>$154.0K</td>
<td>186</td>
<td align="right">65</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$3.65</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$365.00</td>
<td>$123.6K</td>
<td>316</td>
<td align="right">390</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$167.25</td>
<td>$163.3</td>
<td>$165.18</td>
<td>$200.00</td>
<td>$82.5K</td>
<td>12</td>
<td align="right">11</td>
</tr>
</tbody>
</table>
</p>
<h3>About Home Depot</h3>
<p>Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and the 2024 tie-up with SRS will help grow professional demand in roofing, pool and landscaping projects.</p>
<p>Following our analysis of the options activities associated with Home Depot, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Home Depot</h3>
<ul>
<li>With a volume of 2,316,777, the price of HD is up 2.71% at $367.85. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>What The Experts Say On Home Depot</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $418.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Home Depot, targeting a price of $418. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Home Depot with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

What the Options Market Tells Us About Home Depot

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Accenture</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ACN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Accenture.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 35% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 9 are puts, for a total amount of $382,190, and 5 are calls, for a total amount of $183,546.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $350.0 for Accenture over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Accenture's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Accenture's whale trades within a strike price range from $300.0 to $350.0 in the last 30 days. </p>
<h3>Accenture Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451262_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$17.6</td>
<td>$17.4</td>
<td>$17.5</td>
<td>$300.00</td>
<td>$61.2K</td>
<td align="right">358</td>
<td align="right">101</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$17.6</td>
<td>$17.3</td>
<td>$17.6</td>
<td>$300.00</td>
<td>$52.8K</td>
<td align="right">358</td>
<td align="right">52</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$28.3</td>
<td>$25.7</td>
<td>$27.9</td>
<td>$340.00</td>
<td>$50.2K</td>
<td align="right">7</td>
<td align="right">18</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$9.9</td>
<td>$9.6</td>
<td>$9.9</td>
<td>$310.00</td>
<td>$48.5K</td>
<td align="right">149</td>
<td align="right">97</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/04/25</td>
<td>$1.45</td>
<td>$1.1</td>
<td>$1.4</td>
<td>$315.00</td>
<td>$46.7K</td>
<td align="right">59</td>
<td align="right">912</td>
</tr>
</tbody>
</table>
</p>
<h3>About Accenture</h3>
<p>Accenture is a leading global IT services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.</p>
<p>Following our analysis of the options activities associated with Accenture, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Accenture</h3>
<ul>
<li>Trading volume stands at 2,992,244, with ACN's price up by 2.75%, positioned at $312.71.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 81 days.</li>
</ul>
<h3>What Analysts Are Saying About Accenture</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $383.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Accenture, which currently sits at a price target of $372.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on Accenture, maintaining a target price of $390.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Accenture, maintaining a target price of $396.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Accenture, targeting a price of $387.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Accenture with a target price of $370. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Accenture with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


What the Options Market Tells Us About Accenture

<p>In the last three months, 13 analysts have published ratings on Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.4, a high estimate of $22.00, and a low estimate of $16.00. Marking an increase of 4.75%, the current average surpasses the previous average price target of $18.52. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451258_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Invesco by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Etienne Ricard</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.75</td>
<td>$19.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$19.50</td>
<td>$17.00</td>
</tr>
<tr>
<td>Stephen Biggar</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$19.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Invesco. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Invesco compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Invesco's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Invesco's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IVZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Invesco analyst ratings.</strong></a></p>
<h2>About Invesco</h2>
<p>Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of October 2024, the firm had $1.792 trillion in assets under management spread among its equity (58% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (10%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's us retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 29% of its AUM sourced from Europe, Africa, and the Middle East (14%) and Asia (15%).</p>
<h3>Key Indicators: Invesco's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Invesco's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>12.71%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Invesco's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>13.14%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.97%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Invesco's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.77%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Invesco's debt-to-equity ratio is below the industry average at <strong>0.72</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Invesco: Insights From 13 Analyst Reviews

<p>Deep-pocketed investors have adopted a bullish approach towards Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MSFT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 248 extraordinary options activities for Microsoft. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 43% leaning bullish and 39% bearish. Among these notable options, 129 are puts, totaling $9,995,941, and 119 are calls, amounting to $8,253,185.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $530.0 for Microsoft over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Microsoft's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Microsoft's whale activity within a strike price range from $115.0 to $530.0 in the last 30 days. </p>
<h3>Microsoft Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451257_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSFT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.65</td>
<td>$14.55</td>
<td>$14.65</td>
<td>$365.00</td>
<td>$366.2K</td>
<td>3.5K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$0.8</td>
<td>$0.75</td>
<td>$0.8</td>
<td>$390.00</td>
<td>$271.7K</td>
<td>3.3K</td>
<td>12.7K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$19.45</td>
<td>$19.4</td>
<td>$19.4</td>
<td>$375.00</td>
<td>$193.9K</td>
<td>2.1K</td>
<td>118</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$19.4</td>
<td>$19.25</td>
<td>$19.35</td>
<td>$375.00</td>
<td>$193.5K</td>
<td>2.1K</td>
<td>418</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$19.45</td>
<td>$19.35</td>
<td>$19.35</td>
<td>$375.00</td>
<td>$193.5K</td>
<td>2.1K</td>
<td>318</td>
</tr>
</tbody>
</table>
</p>
<h3>About Microsoft</h3>
<p>Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).</p>
<p>In light of the recent options history for Microsoft, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Microsoft's Current Market Status</h3>
<ul>
<li>With a trading volume of 18,083,669, the price of MSFT is down by -1.14%, reaching $374.49.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 24 days from now.</li>
</ul>
<h3>Expert Opinions on Microsoft</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $518.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Microsoft, which currently sits at a price target of $475.<br />
&#x2A; An analyst from Tigress Financial persists with their Buy rating on Microsoft, maintaining a target price of $595.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $550.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Microsoft, targeting a price of $500.<br />
&#x2A; Reflecting concerns, an analyst from Scotiabank lowers its rating to Sector Outperform with a new price target of $470.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Microsoft options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


MSFT

This Is What Whales Are Betting On Microsoft

<p>7 analysts have expressed a variety of opinions on Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $116.86, a high estimate of $150.00, and a low estimate of $78.00. This current average reflects an increase of 33.88% from the previous average price target of $87.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451250_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Corcept Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Corcept Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Corcept Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Corcept Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CORT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Corcept Therapeutics analyst ratings.</strong></a></p>
<h2>Get to Know Corcept Therapeutics Better</h2>
<p>Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.</p>
<h3>Key Indicators: Corcept Therapeutics's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Corcept Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>34.33%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.71%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.61%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Corcept Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.74%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.01</strong>, Corcept Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CORT

Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings)

<p>6 analysts have shared their evaluations of Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $142.33, along with a high estimate of $163.00 and a low estimate of $130.00. A decline of 7.88% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451242_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Qualys by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$130.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$146.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$135.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Walkley</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Qualys. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Qualys compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Qualys's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Qualys's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QLYS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Qualys analyst ratings.</strong></a></p>
<h2>Get to Know Qualys Better</h2>
<p>Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.</p>
<h3>Key Indicators: Qualys's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Qualys displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.11%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Qualys's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>27.62%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Qualys's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.49%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Qualys's ROA excels beyond industry benchmarks, reaching <strong>4.67%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Qualys's debt-to-equity ratio is below the industry average. With a ratio of <b>0.1</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QLYS

The Analyst Verdict: Qualys In The Eyes Of 6 Experts

News

YOSH

Yoshiharu Regains Nasdaq Compliance

<p>In the last three months, 33 analysts have published ratings on Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">22</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">7</td>
<td align="right">11</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $121.91, a high estimate of $160.00, and a low estimate of $72.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.88%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451226_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Trade Desk by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$101.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$101.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$83.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Matthew Condon</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$122.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$103.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$135.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$90.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trade Desk. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Trade Desk compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Trade Desk's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Trade Desk's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TTD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Trade Desk analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Trade Desk</h2>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on devices like computers, smartphones, and connected TVs. It uses data in an iterative manner to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry, and it generates revenue from fees based on a percentage of what its clients spend on advertising.</p>
<h3>Unraveling the Financial Story of Trade Desk</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Trade Desk's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>22.32%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> Trade Desk's net margin is impressive, surpassing industry averages. With a net margin of <strong>24.59%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Trade Desk's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.54%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Trade Desk's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.14%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Trade Desk's debt-to-equity ratio is below the industry average at <strong>0.11</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Trade Desk: 33 Analysts Share Their Views

<p>In the current session, the stock is trading at $86.77, after a <strong>1.07%</strong> spike. Over the past month, <strong>Cava Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>)</strong> stock increased by <strong>0.16%</strong>, and in the past year, by <strong>31.38%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1743451224_0.png" alt="Past Year Chart" /></p>

<h3>Cava Group P/E Compared to Competitors</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Cava Group has a lower P/E than the aggregate P/E of <strong>85.38</strong> of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1743451224_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

CAVA

Price Over Earnings Overview: Cava Group

<p>argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) has outperformed the market over the past 5 years by 17.3% on an annualized basis producing an average annual return of 34.95%. Currently, argenx has a market capitalization of $35.80 billion. </p>
<p><strong>Buying $1000 In ARGX:</strong> If an investor had bought $1000 of ARGX stock 5 years ago, it would be worth <strong>$4,435.15</strong> today based on a price of $589.15 for ARGX at the time of writing.</p>
<h3>argenx's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743451210_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

ARGX

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years

WIIM

The Goodyear Tire & Rubber Company shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy and announced a $13 price target.

<p><strong>Bluebird Bio Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares are trading higher Monday after the company received an unsolicited takeover <a href="https://www.benzinga.com/25/03/44564776/gene-therapy-focused-bluebird-bio-receives-rival-takeover-offer-stock-jumps">offer from Ayrmid Ltd</a>.</p>
<p><strong>What To Know:</strong> The offer includes an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of net sales milestones.</p>
<p>The bid comes after Bluebird had already agreed in February to be acquired and taken private by Carlyle and SK Capital Partners for $3 per share in cash, with the same $6.84 contingent value right. </p>
<p>Bluebird said it previously reviewed strategic alternatives and even engaged in discussions with Ayrmid, but Ayrmid did not submit a proposal at that time. The company's board is now reviewing the new offer with legal and financial advisors. Investors appear to be reacting to the possibility of a higher takeover price.</p>
<p>Bluebird Bio shares are also getting a boost from Barclays on Monday after the analyst firm maintained an <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight rating</a> and set a price target of $8.</p>
<p><strong>Blue Price Action:</strong> BlueBird Bio shares were up 24.1% at $5.06 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-1024x544.png" alt="" class="wp-image-849883" style="width:388px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57.png 1494w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/econ-s/25/03/44567966/stocks-fall-sp-500-eyes-worst-month-in-almost-two-years-oil-rallies-whats-driving-markets-monday">Stocks Fall, S&amp;P 500 Eyes Worst Month In Almost Two Years, Oil Rallies: What&#8217;s Driving Markets Monday?</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Movers

BLUE

BlueBird Shares Are Up Today: What's Going On?

Domino's Pizza shares are trading higher after TD Securities reiterated its buy rating and maintained a $490 price target on the stock.

<hr class="wp-block-separator has-alpha-channel-opacity" />
<p>Something I love about&nbsp;<a href="https://substack.com/redirect/a33e217c-3912-4c2f-8f9e-91aa704311e3?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">Barry Ritholtz's writing</a>&nbsp;is how he often surprises you with unexpected insights.</p>
<p>Sure, he advances well-known — but still underappreciated — wisdom like how&nbsp;<a href="https://substack.com/redirect/b527f577-a1fb-4953-99e9-cd156d26a4bd?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">index fund investing</a>&nbsp;is hard to beat and why&nbsp;<a href="https://substack.com/redirect/bd663486-e3a2-4ec0-a249-1e62906a66d6?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">making short-term market forecasts is futile</a>.</p>
<p>But he offers much more than that.</p>
<p>Take this excerpt on psychology from his new book, "<a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">How Not To Invest</a>," which he shared in a recent piece for&nbsp;<a href="https://substack.com/redirect/af8bee2f-570d-4fcd-a829-2829bdb6c503?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">Bloomberg</a>:</p>
<p><strong><em>Trick Your Lizard Brain</em></strong></p>
<p><em>Nobel laureate Paul Samuelson once said, "Investing should be more like watching paint dry or watching grass grow. If you want excitement, take $800 and go to Las Vegas." While the dopamine hit that comes from a risky stock bet paying off may be enjoyable, passive management is the better option for most investors looking to grow long-term wealth.</em></p>
<p><em>The catch is that you must take steps to protect yourself from, well, yourself. To do so, set up a "mad-money account" — or a cowboy account, as it's sometimes called. Add less than 5% of your liquid capital, so maybe $5,000 if you're liquid enough to have $100,000 as a safety net. Now you can indulge your inner hedge fund manager without jeopardizing anything too material.</em></p>
<p><em>If it works out, you're more likely to let those winners run because it's for fun and not your real money. If it's a debacle, appreciate the terrific lesson that should remind you that this is not your forte.</em></p>
<p>In his book, Barry shares a little more on what he personally does:</p>
<p><em>In my cowboy account, using 2% of my liquid net worth, I play the dumbest game possible: Market timing with out-of-the-money stock option calls…</em></p>
<p>He discusses specific trades he's made. I'll let you buy the book if you really want the details.</p>
<p>Here's his bottom line.</p>
<p><em>Regardless of the results, it allows my inner junkie to leave my main portfolio alone. That is the true value of the cowboy account — my real money remains unmolested by me and my big dumb lizard brain.</em></p>
<p>Like most of us, Barry is not a machine. He is a human with a brain. And when your brain is mismanaged, it can be your worst enemy.</p>
<p>The idea of having a "cowboy account" is not without its issues. Some of you might say it could be a slippery slope towards costlier risk taking. This advice certainly isn't for everybody. But let's also not pretend like living in denial of your instincts and biases isn't risky either.</p>
<p>As TKer subscribers know, my investing mostly consists of&nbsp;<a href="https://substack.com/redirect/e28d3a82-b2cd-452d-881f-d49dc3af9f7d?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">buying and holding passively managed index funds</a>. But while I may have&nbsp;<a href="https://substack.com/redirect/69499d0e-028f-4e14-80f6-5c62a33bd29b?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">lost my taste for picking stocks</a>&nbsp;and timing the market a long time ago, I haven't lost my appetite for risk.</p>
<p>Personally, I've taken Samuelson's advice much more literally. Occasionally, I like to play craps live in a casino. That's the game where you often hear crowds of people cheer loudly as they engage in the mania of a "hot" table. I won't get into too much detail, but it's a game where I can lose enough that it's memorably painful but not so much that it's material to my finances. Importantly, it satiates my risk appetite, and it gives me renewed appreciation for my financial plan at relatively low cost.</p>
<p>In some ways, investing is like dieting: For many people, attempting to cut out junk food entirely just doesn't work.</p>
<p>If you want to learn more about how real people can better navigate the treacherous world of investing, buy Barry's book. He's got real world solutions for your real world challenges.</p>
<p><em>For more info, head to</em>&nbsp;<strong><em><a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">HowNotToInvestBook.com</a></em></strong>&nbsp;»</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td></td>
<td><img loading="lazy" decoding="async" width="550" height="609" src="blob:https://contributor.benzinga.com/6ab83874-4823-43db-a6cf-f0bc4b23db56" /><a href="https://substack.com/redirect/7dcc4b4e-bc26-45cf-8706-e80464a39081?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener"></a></td>
<td></td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>(Source:&nbsp;<a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">How Not To Invest</a>)</p>
<p><strong>&nbsp;Sam Ro mention!</strong></p>
<p>I was shocked and humbled to learn that Barry mentioned me in "<a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">How NOT To Invest</a>." I've been reading his blogs since before the financial crisis. He's had a huge impact on how I think and write about markets.</p>
<p>If you like TKer, then you'll love Barry's writing. Catch up on his views by&nbsp;<a href="https://substack.com/redirect/2235c538-5abb-496b-bb99-5bb8c6756d36?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">reading his book</a>!</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td></td>
<td><img loading="lazy" decoding="async" width="550" height="410" src="blob:https://contributor.benzinga.com/c52a613c-0da2-46f1-9062-0366e83cc0b6" /><a href="https://substack.com/redirect/5b122bfa-6cc5-4129-bd35-103393fb06a0?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener"></a></td>
<td></td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p>From "How NOT To Invest"</p>


Broad U.S. Equity ETFs

Opinion

Personal Finance

Reviews

Taming My 'Big Dumb Lizard Brain' With A 'Cowboy Account'

CTVA

Corteva shares are trading higher after Argus Research upgraded the stock from Hold to Buy.

<p><strong>Lucid Group Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares are trading higher on Monday in potential reaction to bullish commentary <a href="https://www.benzinga.com/25/03/44560524/auto-stocks-skid-after-trump-shrugs-off-higher-prices-should-you-buy-the-dip">from a company executive</a>.</p>
<p><strong>What Happened:</strong> According to an Elektrek <a href="https://electrek.co/2025/03/31/lucid-lcid-orders-surge-former-tesla-drivers-flock-other-evs/">report</a> citing an interview with Fox Business, Lucid is seeing a &#8220;dramatic uptick&#8221; in orders from former <strong>Tesla Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) customers. </p>
<p>Lucid interim CEO <strong>Marc Winteroff </strong>reportedly said at the end of last week that 50% of orders over the past two months have come from former Tesla drivers. He cited &#8220;negative feelings&#8221; about Tesla CEO <strong>Elon Musk</strong> as the main reason for the acceleration in interest in Lucid vehicles. </p>
<p>Tesla property has been vandalized in recent months in response to Musk&#8217;s involvement with the Department of Government Efficiency and close ties to the Trump administration. Tesla shares are down about 35% year-to-date on rising investor concerns about permanent brand damage.</p>
<p>Winteroff reportedly said that Tesla owners are looking at all options to get rid of their Teslas. Although former Tesla owners have &#8220;always been a source&#8221; of new customers for Lucid, more and more owners have been looking to make the switch in recent months, he added.</p>
<p>Lucid reported <a href="https://www.benzinga.com/news/earnings/25/02/43957497/lucid-q4-earnings-revenue-beat-eps-beat-20k-production-guidance-for-2025-ceo-transition-and-more">fourth-quarter financial results</a> near the end of February that came in ahead of analyst expectations. The EV maker said it produced 3,386 vehicles in the fourth quarter and delivered 3,099 vehicles.&nbsp;Lucid expects to produce approximately 20,000 vehicles in 2025.</p>
<p><strong>LCID Price Action:</strong> <a href="http://benzinga.com/quote/lcid">Lucid shares</a> were up 4.74% at $2.43 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/25/03/44560524/auto-stocks-skid-after-trump-shrugs-off-higher-prices-should-you-buy-the-dip"><strong>Auto Stocks Skid After Trump Shrugs Off Higher Prices &#8211; Should You Buy The Dip?</strong></a></li>
</ul>
<p><em>Photo: courtesy of Lucid.</em></p>


LCID

TSLA

What's Going On With Lucid Stock Today?

<p>While <strong>President Donald Trump</strong> hammers home an economic policy with an <a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">array of tariffs</a>, he may face an unintended consequence: a nationwide toilet paper shortage. </p>
<p>If so, the event would <a href="https://cnr.ncsu.edu/news/2020/05/coronavirus-toilet-paper-shortage/">spark</a> painful memories of COVID-19. Such an outcome might benefit consumer goods giant <strong>Kimberly-Clark Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>). </p>
<p>According to a Bloomberg <a href="https://www.yahoo.com/news/trumps-tariffs-may-cause-toilet-190300908.html">report</a>, the Trump administration's plans to increase levies on Canadian softwood lumber to 27% — and possibly to over 50% at some point later — may negatively impact the supply of northern bleached softwood kraft pulp, or NBSK. This is a key component found in toilet paper and paper towels.</p>
<p>Driving the headwind against the delicate supply chain is the financial impact of the aforementioned import taxes, which threatens to put some sawmills out of business. Subsequently, the elimination of vital entities would reduce the supply of wood chips to make pulp. A domino effect may materialize, leading to temporary closures and lower production of NBSK.</p>
<p>Downstream to the consumer, the end result could possibly be pandemic-like shortages of toilet paper and related products, which may eventually metastasize into higher prices. Considering that many households will acutely recall the shortages during the COVID-19 crisis, hoarding behavior wouldn't be out of the question. </p>
<p>From a cynical perspective, this narrative could benefit Kimberly-Clark&#8217;s stock, which is unexciting in any other circumstance.</p>
<h2 class="wp-block-heading">An Unusual Twist Catapults KMB Stock to Relevance</h2>
<p>While the concept of another round of toilet-paper hoarding may sound alarmist, it seems that Wall Street is getting the message. Consider the benchmark exchange-traded fund <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which is down roughly 6% on a year-to-date basis. In contrast, during the same period, Kimberly-Clark stock finds itself up nearly 8%.</p>
<p>Adding to the unusual toilet paper conundrum, replacing the pulp imported from Canada — which clocks in at about 2 million tons — will not be an easy task. For one thing, Canada supplies most of the ingredient that American consumers use. Second, many U.S. paper plants depend on Canadian mills due to processing calibrated for NBSK specifically.</p>
<p>To be sure, cooler diplomatic heads can still prevail. At the same time, the U.S. and Canada have <a href="https://www.benzinga.com/politics/25/03/44206362/canada-claps-back-at-unjustified-trump-tariffs-on-dairy-lumber">longstanding disputes over lumber</a>, along with dairy. Per a Benzinga report, American lumber producers claim that Canada&#8217;s system effectively subsidizes its industry, a charge that the Canadian government denies. Prior to the latest round of tariffs, U.S. duties on Canadian lumber ranged from 11.5% to 17.3%.</p>
<p>Undeniably, 2025 has gotten off to a messy start for multiple sectors. That said, one of the few confidence-inspiring winners is KMB stock. Frankly, the underlying enterprise offers product categories that cannot be avoided nor indefinitely deferred. This reality may attract conservative, buy-and-hold investors.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31145908/KMB-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-849847" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31145908/KMB-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31145908/KMB-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31145908/KMB-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31145908/KMB-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure></p>
<p>At the same time, the relevancy bump in KMB stock also makes it appealing as a trading prospect. As one might expect, KMB features a gentle upward bias. Based on pricing data from January 2019 onward, a long position held for any given eight-week period has a 54% chance of being profitable. Further, dynamic conditions — such as heightened fear or greed — do not materially change the security's reliable nature.</p>
<h2 class="wp-block-heading">Crafting Options Strategies for Kimberly-Clark</h2>
<p>Investors who wish to be proactive about the TP conundrum — aside from making a quick grocery run to beat the crowd — can choose to trade Kimberly-Clark options. One idea is to deploy a credit-based options strategy called the bull put spread.</p>
<p>For the options chain expiring April 17, a trader may consider selling the 140/135 bull put spread. This transaction involves selling the $140 put (at a time-of-writing bid of $150) and simultaneously buying the $135 put (at an ask of $60), resulting in a cash inflow of $90.</p>
<p>So long as KMB stock stays above the higher strike price of $140, the trader gets to keep the $90. However, if the security tanks, the maximum loss would come out to $410.</p>
<p>Another approach, which is a debit-based approach, is to consider a bull call spread. For the April 17 expiration date, aggressive traders may consider the 143/145 bull spread. This transaction involves buying the $143 call (at a $180 ask) and simultaneously selling the $145 call (at a $90 bid), resulting in a cash outflow of $90.</p>
<p>Should the Kimberly-Clark share price hit the $145 target at the expiration date — which is reasonable given historical trends — the payout is the difference between the strike prices (multiplied by 100 shares) minus the net debit paid, or $110. That would be a 122.22% payout, which would go a long way in easing the pain from the possible TP shortage.</p>
<p><strong>Now Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/econ-s/25/03/44567966/stocks-fall-sp-500-eyes-worst-month-in-almost-two-years-oil-rallies-whats-driving-markets-monday">Stocks Fall, S&amp;P 500 Eyes Worst Month In Almost Two Years, Oil Rallies: What&#8217;s Driving Markets Monday?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Equities

Long Ideas

Politics

Options Corner: Wipe Away 'TP' Shortage Concerns With Kimberly-Clark

<p><a href="https://x.com/sama/status/1906793591944646898?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet" title="https://x.com/sama/status/1906793591944646898?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet">https://x.com/sama/status/1906793591944646898?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet</a></p>


GOOG

GOOGL

NVDA

Sam Altman Says 'we are planning to release our first open-weigh language model since GPT-2.'

CTRA

TRGP

Shares of energy stocks are trading higher amid strength in oil and natural gas prices.

Press Releases

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Events

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals Announces Reverse Stock Split

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

AKTX

AMIX

AREC

CNSP

HURA

NVNO

OTLK

PALI

Akanda

Artelo Biosciences

CNS Pharma

Enveric Biosciences

Eyenovia

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Jaguar Health

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Virpax Pharmaceuticals, Inc. - Common Stock

Comments

CNS Pharma

Intérêt court

CNS Pharma (NASDAQ:CNSP) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL